{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"36"}],"title":"Number of subjects without recrudescence or development of Acute GVHD symptoms post CAR T infusion"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}],"title":"Number of subjects with recrudescence or development of Acute GVHD symptoms post CAR T infusion"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"36"}],"units":"Participants"}],"groups":[{"description":"This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\\^5 CAR T cells/kg","id":"OG000","title":"Phase 1 - Cohort 1A"},{"description":"This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\\^6 CAR T cells/kg","id":"OG001","title":"Phase 1-Cohort 1B"},{"description":"This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\\^6 CAR T cells/kg","id":"OG002","title":"Phase 1-Cohort 1C"},{"description":"This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\\^7 CAR T cells/kg","id":"OG003","title":"Phase 1-Cohort 1D"},{"description":"This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\\^5 CAR T cells/kg following prescribed lymphodepletion with fludarabine and cyclophosphamide","id":"OG004","title":"Phase 1-Cohort 1F1"},{"description":"This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\\^6 CAR T cells/kg following prescribed lymphodepletion with fludarabine and cyclophosphamide","id":"OG005","title":"Phase 1-Cohort 1F2"},{"description":"The phase 2 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\\^6 CAR T cells/kg following lymphodepletion if indicated","id":"OG006","title":"Phase 2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Number of participants with a history of prior allogeneic HSCT (hematopoietic stem cell transplantation) who received CAR T infusion","reportingStatus":"POSTED","timeFrame":"Initial CAR T Infusion through Day 63 post infusion assessment (+/- 14 days)","title":"Number of Participants With Recrudescence or Development of Acute GVHD (Graft Versus Host Disease) Symptoms Post CAR T Infusion","type":"SECONDARY","unitOfMeasure":"Participants"}